[an error occurred while processing this directive]
  3 by 5 Initiative > Media centre
printable version

WHO, UNAIDS and UNICEF modify recommendations for cotrimoxazole prophylaxis in children: Previous page | 1,2,3,4,5,6,7,8,9,10,11

Under what circumstances should cotrimoxazole be discontinued:

  
  • Occurrence of severe cutaneous reactions such as Stevens Johnson syndrome, renal and/or hepatic insufficiency or severe hematological toxicity.
  • In an HIV exposed child ONLY once HIV infection has confidently been excluded;
    - For a non-breastfeeding child <18 months of age this is by negative DNA or RNA virological HIV testing
    - For a breastfed HIV exposed child < 18months – negative virological testing is only reliable if conducted 6 weeks after cessation of breastfeeding,
    - For a breastfed HIV-exposed child >18 months - negative HIV antibody testing 3 months after stopping breastfeeding
    - In an HIV-infected child:
    - If the child is on ARV therapy, cotrimoxazole can be stopped ONLY when evidence of immune restoration has occurred. This can be assumed where the child is over 18 months of age and CD4% >15 at two measurements, at least 3 to 6 months apart. If a CD4 count is not available, cotrimoxazole should not be stopped before a full 6 months of successful adherence to ARV therapy, and then only when clinical evidence of immune restoration is present. Continuing cotrimoxazole may continue to provide benefit even once child has clinically improved.
    - If ARV therapy is not available it should not be discontinued

WHO, UNAIDS and UNICEF modify recommendations for cotrimoxazole prophylaxis in children: 1,2,3,4,5,6,7,8,9,10,11 | Next page

[an error occurred while processing this directive]